Form 4 for ATOS ATOSSA THERAPEUTICS, INC.
Accepted 2026-03-31 00:00:00 ET · period of report 2026-03-27 · accession 0001193125-26-134861 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 2026-03-27 | ATOS | QUAY STEVEN C | Pres, CEO, Dir | A - Grant | $0.00 | +65.0K | 88.0K | +282% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-27 | A | A | 65,000 | $0.00 | 88,038 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. (F2) On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. |